Walsh said the three most common conditions he sees include a pinched nerve, spine arthritis, and spine misalignment.
AbbVie reported positive results from a Phase 3 trial of Rinvoq to treat ankylosing spondylitis, an arthritis affecting primarily the spine. AbbVie (ABBV) on Thursday reported progress in a Phase 3 ...
Hosted on MSN
What you need to know about arthritis, from causes and management to emerging treatment
Arthritis is a complex and often misunderstood condition that affects millions of individuals worldwide. It is not a single disease but rather an umbrella term that encompasses over 100 types of joint ...
DEAR MAYO CLINIC: I am in my late 50s and have started having stiffness in my back. I have become much less flexible and sometimes even have a hard time looking over my shoulder. I remember my ...
More than 58 million Americans live with arthritis, often managing pain through shots that only last around six months before more are needed. For many, that leads to a tough choice: keep getting ...
Chronic pain sufferers in the Algoma region now have access to a groundbreaking new treatment: the Neurolyser XR HIFU system ...
AbbVie is hoping the FDA will green light Rinvoq to treat adults with a type of back arthritis. If eventually approved by the FDA, this would be the fourth approved indication in the U.S. for Rinvoq.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback